AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
ESSA Pharma Statistics
Share Statistics
ESSA Pharma has 44.37M shares outstanding. The number of shares has increased by 0.3% in one year.
Shares Outstanding | 44.37M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 43.38M |
Failed to Deliver (FTD) Shares | 90 |
FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 691.47K, so 1.56% of the outstanding shares have been sold short.
Short Interest | 691.47K |
Short % of Shares Out | 1.56% |
Short % of Float | 1.59% |
Short Ratio (days to cover) | 0.32 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -3.72.
PE Ratio | 0 |
Forward PE | -3.72 |
PS Ratio | 0 |
Forward PS | 3.5 |
PB Ratio | 2.09 |
P/FCF Ratio | -11.81 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for ESSA Pharma Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.64, with a Debt / Equity ratio of 0.
Current Ratio | 38.64 |
Quick Ratio | 38.64 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is 0%.
Return on Equity (ROE) | 0% |
Return on Assets (ROA) | 0% |
Return on Capital (ROIC) | 0% |
Revenue Per Employee | 0 |
Profits Per Employee | 0 |
Employee Count | 50 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -80.63% in the last 52 weeks. The beta is 1.84, so ESSA Pharma 's price volatility has been higher than the market average.
Beta | 1.84 |
52-Week Price Change | -80.63% |
50-Day Moving Average | 1.8 |
200-Day Moving Average | 4.89 |
Relative Strength Index (RSI) | 43.36 |
Average Volume (20 Days) | 1.03M |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | 0 |
Net Income | 0 |
EBITDA | 0 |
EBIT | n/a |
Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 103.71M in cash and 329.26K in debt, giving a net cash position of 103.38M.
Cash & Cash Equivalents | 103.71M |
Total Debt | 329.26K |
Net Cash | 103.38M |
Retained Earnings | 0 |
Total Assets | 128.11M |
Working Capital | 124.26M |
Cash Flow
In the last 12 months, operating cash flow was -22.72M and capital expenditures 0, giving a free cash flow of -22.72M.
Operating Cash Flow | -22.72M |
Capital Expenditures | 0 |
Free Cash Flow | -22.72M |
FCF Per Share | -0.51 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
EPIX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -36.16% |
FCF Yield | -28.84% |
Analyst Forecast
The average price target for EPIX is $2, which is 13% higher than the current price. The consensus rating is "Hold".
Price Target | $2 |
Price Target Difference | 13% |
Analyst Consensus | Hold |
Analyst Count | 3 |
Stock Splits
The last stock split was on Apr 25, 2018. It was a backward split with a ratio of 1:20.
Last Split Date | Apr 25, 2018 |
Split Type | backward |
Split Ratio | 1:20 |
Scores
Altman Z-Score | 12.73 |
Piotroski F-Score | 1 |